Page 33 - GTM-3-3

Global Translational Medicine Computational advances in cancer liquid biopsy

One of the key aims of this review is to foster tumors. Cancers (Basel). 2021;13(21):5429.
collaboration and synergy among the complementary doi: 10.3390/cancers13215429
communities involved in liquid biopsy sample screening.
This effort should encompass bioinformaticians, 4. Mittal K, Koon H, Elson P, et al. Dual VEGF/VEGFR
statisticians, laboratory technicians, biologists, and inhibition in advanced solid malignancies: Clinical effects
and pharmacodynamic biomarkers. Cancer Biol Ther.
clinicians. By providing a comprehensive overview of 2014;15(8):975-981.
the computational steps involved, we strive to facilitate a
clearer understanding and appreciation of the complexities doi: 10.4161/cbt.29187
inherent in liquid biopsy analysis. By leveraging each 5. Jin Z, Sinicrope FA. Advances in the therapy of BRAF V600E
other’s expertise and perspectives, we can collectively metastatic colorectal cancer. Expert Rev Anticancer Ther.
advance the field of liquid biopsy research and its clinical 2019;19(9):823-829.
applications. doi: 10.1080/14737140.2019.1661778
Acknowledgments 6. Diaz LA Jr., Williams RT, Wu J, et al. The molecular
evolution of acquired resistance to targeted EGFR blockade
I acknowledge the people I work with on liquid biopsy- in colorectal cancers. Nature. 2012;486(7404):537-540.
related projects: E. S. Famulari, V. Rossella, C. Felici, V.
Giansanti, D. Cittaro, G. Bucci, G. Di Sario, D. Lazarevich, doi: 10.1038/nature11219
F. Giannese, M. J. Morelli, M. Alfano, and G. Tonon. 7. Amelio I, Bertolo R, Bove P, et al. Liquid biopsies and cancer
omics. Cell Death Discov. 2020;6(1):131.
Funding
doi: 10.1038/s41420-020-00373-0
None.
8. Pinzani P, D’Argenio V, Del Re M, et al. Updates on
Conflict of interest liquid biopsy: Current trends and future perspectives for
clinical application in solid tumors. Clin Chem Lab Med.
The author declares that she has no competing interests. 2021;59(7):1181-1200.

Author contributions doi: 10.1515/cclm-2020-1685
9. Schwarze K, Buchanan J, Fermont JM, et al. The complete
This is a single-authored article.
costs of genome sequencing: A microcosting study in cancer
Ethics approval and consent to participate and rare diseases from a single center in the United Kingdom.
Genet Med. 2020;22(1):85-94.
Not applicable. doi: 10.1038/s41436-019-0618-7

Consent for publication 10. Wan JCM, Heider K, Gale D, et al. ctDNA monitoring using
patient-specific sequencing and integration of variant reads.
Not applicable. Sci Transl Med. 2020;12(548):eaaz8084.
Availability of data doi: 10.1126/scitranslmed.aaz8084

Not applicable. 11. Rose Brannon A, Jayakumaran G, Diosdado M, et al.
Enhanced specificity of clinical high-sensitivity tumor
References mutation profiling in cell-free DNA via paired normal
sequencing using MSK-ACCESS. Nat Commun.
1. Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, 2021;12(1):3770.
Roehrl MHA, Barrera-Saldaña HA. The dawn of the
liquid biopsy in the fight against cancer. Oncotarget. doi: 10.1038/s41467-021-24109-5
2018;9(2):2912-2922. 12. Bauml J, Levy B. Clonal hematopoiesis: A new layer in
doi: 10.18632/oncotarget.23131 the liquid biopsy story in lung cancer. Clin Cancer Res.
2018;24(18):4352-4354.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World
Health Organization classification of tumors of the central doi: 10.1158/1078-0432.CCR-18-0969
nervous system: A summary. Acta Neuropathol (Berl). 13. Bettegowda C, Sausen M, Leary RJ, et al. Detection of
2016;131(6):803-820.
circulating tumor DNA in early- and late-stage human
doi: 10.1007/s00401-016-1545-1 malignancies. Sci Transl Med. 2014;6(224):224ra24.
3. Eibl RH, Schneemann M. Liquid biopsy and primary brain doi: 10.1126/scitranslmed.3007094

Volume 3 Issue 3 (2024) 10 doi: 10.36922/gtm.3063